Cellular transduction mechanisms of adeno-associated viral vectors

Current Opinion in Virology

Volumn 21, Issue , 2016, Pages 54-60

  Berry, Garrett Edward ^a,b   Asokan, Aravind ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

CELL MIGRATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HOST CELL; HUMAN; NONHUMAN; NUCLEAR IMPORT; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE THERAPY; VIRUS ENTRY; VIRUS GENOME; VIRUS RECOMBINANT; DEPENDOPARVOVIRUS; DRUG DELIVERY SYSTEM; GENE THERAPY; GENE VECTOR; GENETICS;

DEPENDOVIRUS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; TRANSDUCTION, GENETIC;

EID: 84982170186     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.08.001     Document Type: Review

References (60)

1. 1 Atchison, R.W., Casto, B.C., Hammon, W.M., Adenovirus-associated defective virus particles. Science 149 (1965), 754–756.
2. 2 Bowles, D.E., Rabinowitz, J.E., Samulski, R.J., The genus Dependovirus. Kerr, J.R., Cotmore, S.F., Bloom, M.E., Linden, R.M., Parrish, C.R., (eds.) Parvoviruses, 2006, New York, Edward Arnold Ltd., 15–24.
3. 3 Geoffroy, M.C., Salvetti, A., Helper functions required for wild type and recombinant adeno-associated virus growth. Curr Gene Ther 5 (2005), 265–271.
4. 4 Grieger, J.C., Samulski, R.J., Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507 (2012), 229–254.
5. 5 Xiao, P.J., Li, C., Neumann, A., Samulski, R.J., Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol Ther 20 (2012), 317–328.
6. 6 Huang, L.Y., Halder, S., Agbandje-McKenna, M., Parvovirus glycan interactions. Curr Opin Virol 7C (2014), 108–118.
7. 7 Duan, D., Li, Q., Kao, A.W., Yue, Y., Pessin, J.E., Engelhardt, J.F., Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 73 (1999), 10371–10376.
8. 8 Bartlett, J.S., Wilcher, R., Samulski, R.J., Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74 (2000), 2777–2785.
9. 9 Di Pasquale, G., Chiorini, J.A., AAV transcytosis through barrier epithelia and endothelium. Mol Ther 13 (2006), 506–516.
10. 10• Nonnenmacher, M., Weber, T., Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10 (2011), 563–576 This study identified the CLIC/GEEC pathway as a route of productive AAV cellular uptake. This is the first study to implicate this pathway in AAV trafficking.
11. 11 Sanlioglu, S., Benson, P.K., Yang, J., Atkinson, E.M., Reynolds, T., Engelhardt, J.F., Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 74 (2000), 9184–9196.
12. 12• Weinberg, M.S., Nicolson, S., Bhatt, A.P., McLendon, M., Li, C., Samulski, R.J., Recombinant adeno-associated virus utilizes cell-specific infectious entry mechanisms. J Virol 88 (2014), 12472–12484 This study demonstrated that inhibition of macropinocytosis has cell-specific effects on AAV transduction, enhancing transduction in some cell types while inhibiting transduction in others. This study highlights the existence of host cell-specific entry pathways.
13. 13 Harbison, C.E., Lyi, S.M., Weichert, W.S., Parrish, C.R., Early steps in cell infection by parvoviruses: host-specific differences in cell receptor binding but similar endosomal trafficking. J Virol 83 (2009), 10504–10514.
14. 14 Ding, W., Zhang, L.N., Yeaman, C., Engelhardt, J.F., rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 13 (2006), 671–682.
15. 15 Castle, M.J., Perlson, E., Holzbaur, E.L., Wolfe, J.H., Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment. Mol Ther 22 (2014), 554–566.
16. 16 Bantel-Schaal, U., Hub, B., Kartenbeck, J., Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol 76 (2002), 2340–2349.
17. 17 Johnson, J.S., Li, C., DiPrimio, N., Weinberg, M.S., McCown, T.J., Samulski, R.J., Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84 (2010), 8888–8902.
18. 18 Johnson, J.S., Gentzsch, M., Zhang, L., Ribeiro, C.M., Kantor, B., Kafri, T., Pickles, R.J., Samulski, R.J., AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog, 7, 2011, e1002053.
19. 19 Douar, A.M., Poulard, K., Stockholm, D., Danos, O., Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 75 (2001), 1824–1833.
20. 20 Nonnenmacher, M.E., Cintrat, J.C., Gillet, D., Weber, T., Syntaxin 5-dependent retrograde transport to the trans-Golgi network is required for adeno-associated virus transduction. J Virol 89 (2015), 1673–1687 This study identified the protein syntaxin 5 as an indispensable protein for the trafficking of AAV to the trans-Golgi network. This study demonstrated that knockdown and chemical inhibition of syntaxin 5 strongly inhibited AAV transduction.
21. 21 Berry, G.E., Asokan, A., Chemical modulation of endocytic sorting augments adeno-associated viral transduction. J Biol Chem 291 (2016), 939–947.
22. 22•• Pillay, S., Meyer, N.L., Puschnik, A.S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L.T., Wosen, J.E., Nagamine, C.M., Chapman, M.S., Carette, J.E., An essential receptor for adeno-associated virus infection. Nature 530 (2016), 108–112 This is the first study to identify a universal receptor for AAV, termed AAVR. This landmark study used both in vitro and in vivo studies to confirm the role of AAVR in the transduction of several AAV serotypes.
23. 23 Girod, A., Wobus, C.E., Zadori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J.A., Hallek, M., The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 83 (2002), 973–978.
24. 24 Stahnke, S., Lux, K., Uhrig, S., Kreppel, F., Hosel, M., Coutelle, O., Ogris, M., Hallek, M., Buning, H., Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 409 (2011), 77–83.
25. 25 Grieger, J.C., Johnson, J.S., Gurda-Whitaker, B., Agbandje-McKenna, M., Samulski, R.J., Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol 81 (2007), 7833–7843.
26. 26 Nam, H.J., Gurda, B.L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., Agbandje-McKenna, M., Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J Virol 85 (2011), 11791–11799.
27. 27 Kronenberg, S., Bottcher, B., von der Lieth, C.W., Bleker, S., Kleinschmidt, J.A., A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol 79 (2005), 5296–5303.
28. 28 Sonntag, F., Bleker, S., Leuchs, B., Fischer, R., Kleinschmidt, J.A., Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 80 (2006), 11040–11054.
29. 29 Salganik, M., Venkatakrishnan, B., Bennett, A., Lins, B., Yarbrough, J., Muzyczka, N., Agbandje-McKenna, M., McKenna, R., Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86 (2012), 11877–11885.
30. 30 Grieger, J.C., Snowdy, S., Samulski, R.J., Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol 80 (2006), 5199–5210.
31. 31• Nicolson, S.C., Samulski, R.J., Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 88 (2014), 4132–4144 This is the first study to definitively demonstrate the mechanism of AAV transport into the nucleus is through the nuclear pore complex. The authors demonstrated that the importinβ family of proteins are important for this process.
32. 32 Kelich, J.M., Ma, J., Dong, B., Wang, Q., Chin, M., Magura, C.M., Xiao, W., Yang, W., Super-resolution imaging of nuclear import of adeno-associated virus in live cells. Mol Ther Methods Clin Dev, 2, 2015, 15047.
33. 33 Qiu, J., Brown, K.E., A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. Virology 257 (1999), 373–382.
34. 34 Bevington, J.M., Needham, P.G., Verrill, K.C., Collaco, R.F., Basrur, V., Trempe, J.P., Adeno-associated virus interactions with B23/Nucleophosmin: identification of sub-nucleolar virion regions. Virology 357 (2007), 102–113.
35. 35 Johnson, J.S., Samulski, R.J., Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83 (2009), 2632–2644.
36. 36 Horowitz, E.D., Rahman, K.S., Bower, B.D., Dismuke, D.J., Falvo, M.R., Griffith, J.D., Harvey, S.C., Asokan, A., Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 87 (2013), 2994–3002.
37. 37 Ferrari, F.K., Samulski, T., Shenk, T., Samulski, R.J., Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70 (1996), 3227–3234.
38. 38 Qing, K., Wang, X.S., Kube, D.M., Ponnazhagan, S., Bajpai, A., Srivastava, A., Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci U S A 94 (1997), 10879–10884.
39. 39 Qing, K., Khuntirat, B., Mah, C., Kube, D.M., Wang, X.S., Ponnazhagan, S., Zhou, S., Dwarki, V.J., Yoder, M.C., Srivastava, A., Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 72 (1998), 1593–1599.
40. 40 Choi, V.W., McCarty, D.M., Samulski, R.J., Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol 80 (2006), 10346–10356.
41. 41 Schwartz, R.A., Palacios, J.A., Cassell, G.D., Adam, S., Giacca, M., Weitzman, M.D., The Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication. J Virol 81 (2007), 12936–12945.
42. 42 Lentz, T.B., Samulski, R.J., Insight into the mechanism of inhibition of adeno-associated virus by the Mre11/Rad50/Nbs1 complex. J Virol 89 (2015), 181–194.
43. 43 Zentilin, L., Marcello, A., Giacca, M., Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 75 (2001), 12279–12287.
44. 44 Choi, V.W., Samulski, R.J., McCarty, D.M., Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol 79 (2005), 6801–6807.
45. 45• Salganik, M., Aydemir, F., Nam, H.J., McKenna, R., Agbandje-McKenna, M., Muzyczka, N., Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88 (2014), 1071–1079 This study identified AAV capsid mutants that trafficked normally but were defective for either RNA transcription or second-strand synthesis. This is the first study to demonstrate a possible role for the AAV capsid in transduction after uncoating and genome release.
46. 46•• Schreiber, C.A., Sakuma, T., Izumiya, Y., Holditch, S.J., Hickey, R.D., Bressin, R.K., Basu, U., Koide, K., Asokan, A., Ikeda, Y., An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses. PLoS Pathog, 11, 2015, e1005082 This study reports the interaction of AAV with the U2 snRNP spliceosome and identifies the complex as an AAV restriction factor. Further, the authors demonstrated a pharmacological approach to increase AAV transduction through inhibition U2 snRNP-related proteins.
47. 47 Yan, Z., Zak, R., Luxton, G.W., Ritchie, T.C., Bantel-Schaal, U., Engelhardt, J.F., Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 76 (2002), 2043–2053.
48. 48 Yan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., Engelhardt, J.F., Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 78 (2004), 2863–2874.
49. 49 Nathwani, A.C., Cochrane, M., McIntosh, J., Ng, C.Y., Zhou, J., Gray, J.T., Davidoff, A.M., Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther 16 (2009), 60–69.
50. 50 Mitchell, A.M., Samulski, R.J., Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. J Virol 87 (2013), 13035–13041.
51. 51 Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J., Kirk, C.J., Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17 (2011), 2734–2743.
52. 52 Zhong, L., Qing, K., Si, Y., Chen, L., Tan, M., Srivastava, A., Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90. J Biol Chem 279 (2004), 12714–12723.
53. 53 Mitchell, A.M., Li, C., Samulski, R.J., Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J Virol 87 (2013), 4571–4583.
54. 54 Wang, Q., Mora-Jensen, H., Weniger, M.A., Perez-Galan, P., Wolford, C., Hai, T., Ron, D., Chen, W., Trenkle, W., Wiestner, A., Ye, Y., ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106 (2009), 2200–2205.
55. 55 Brem, G.J., Mylonas, I., Bruning, A., Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol Oncol 128 (2013), 383–390.
56. 56 Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H. Jr., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., Muzyczka, N., Srivastava, A., Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A 105 (2008), 7827–7832.
57. 57 Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., Muzyczka, N., Srivastava, A., Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381 (2008), 194–202.
58. 58 Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.H., Chiodo, V., Pang, J.J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A.S., Hauswirth, W.W., High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17 (2009), 463–471.
59. 59 Ling, C., Li, B., Ma, W., Srivastava, A., Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses. Hum Gene Ther Methods, 2016 [Epub ahead of print].
60. 60 McCarty, D.M., Monahan, P.E., Samulski, R.J., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8 (2001), 1248–1254.